BioAcyl Corp
BioAcyl Corp |
|
 |
 |
 |
|
Hassan, A. O., Kafai, N. M., Dmitriev, I. P., & others. (2020). A single-dose intranasal chad vaccine protects upper and lower respiratory tracts against sars-cov-2. Cell, 183(1), 169–184.e13. Added by: Dr. Enrique Feoli (25/04/2021, 16:05) Last edited by: Dr. Enrique Feoli (25/04/2021, 16:11) |
 |
| Resource type: Journal Article DOI: 10.1016/j.cell.2020.08.026 ID no. (ISBN etc.): 0092-8674 BibTeX citation key: Hassan2020 View all bibliographic details  |
Categories: BioAcyl Corp, BioAcyl Corp Subcategories: COVID-19, Inmunidad de mucosas Creators: Dmitriev, Hassan, Kafai, others Collection: Cell |
Views: 2/327
|
| Abstract |
|
The coronavirus disease 2019 pandemic has made deployment of an effective vaccine a global health priority. We evaluated the protective activity of a chimpanzee adenovirus-vectored vaccine encoding a prefusion stabilized spike protein (ChAd-SARS-CoV-2-S) in challenge studies with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and mice expressing the human angiotensin-converting enzyme 2 receptor. Intramuscular dosing of ChAd-SARS-CoV-2-S induces robust systemic humoral and cell-mediated immune responses and protects against lung infection, inflammation, and pathology but does not confer sterilizing immunity, as evidenced by detection of viral RNA and induction of anti-nucleoprotein antibodies after SARS-CoV-2 challenge. In contrast, a single intranasal dose of ChAd-SARS-CoV-2-S induces high levels of neutralizing antibodies, promotes systemic and mucosal immunoglobulin A (IgA) and T cell responses, and almost entirely prevents SARS-CoV-2 infection in both the upper and lower respiratory tracts. Intranasal administration of ChAd-SARS-CoV-2-S is a candidate for preventing SARS-CoV-2 infection and transmission and curtailing pandemic spread.
Added by: Dr. Enrique Feoli Last edited by: Dr. Enrique Feoli |
